Challenges and opportunities during the COVID-19 pandemic: Treating patients for substance use disorders during the perinatal period.
Alcohol
COVID-19
Opioid use disorder
Pandemic
Postpartum
Pregnancy
Substance use disorder
Journal
Preventive medicine
ISSN: 1096-0260
Titre abrégé: Prev Med
Pays: United States
ID NLM: 0322116
Informations de publication
Date de publication:
11 2021
11 2021
Historique:
received:
08
02
2021
revised:
05
06
2021
accepted:
18
07
2021
pubmed:
25
7
2021
medline:
29
10
2021
entrez:
24
7
2021
Statut:
ppublish
Résumé
The coronavirus disease 2019 (COVID-19) pandemic exacerbated the opioid use disorder epidemic and accelerated alcohol and other substance use disorders. Sudden health care service delivery changes during the COVID-19 pandemic created both challenges and opportunities for all patients with substance use disorders including the use of virtual or telemedicine visits, medication access issues and ensuring access to naloxone when supplies cannot be handed out. Unique challenges for pregnant and post-partum patients with substance use disorders includes some evidence of reduced access to medication to treat opioid use disorders and changes in delivery protocols that isolate birthing people from supports. Opportunities for all patients with substance use disorders include virtual platforms presenting positive opportunities for treatment. They are time efficient, eliminate transportation barriers, and potentially reduce childcare barriers. For pregnant and post-partum patients with substance use disorders, hybrid models of telemedicine and in-person visits reduced no-show visit rates and increased flexibility in medication dosing regimens. Thus, there is a unique opportunity to study the success of different virtual care models given the variety of implemented strategies. The COVID-19 pandemic provides an unprecedented opportunity to dramatically transform standard care approaches to help optimize care for all patients, including pregnant and post-partum people.
Identifiants
pubmed: 34302836
pii: S0091-7435(21)00311-X
doi: 10.1016/j.ypmed.2021.106742
pmc: PMC8389664
mid: NIHMS1731218
pii:
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
106742Subventions
Organisme : NIDA NIH HHS
ID : R01 DA047867
Pays : United States
Informations de copyright
Copyright © 2021 Elsevier Inc. All rights reserved.
Références
Am J Perinatol. 2020 Jun;37(8):800-808
pubmed: 32396948
Addict Behav. 2015 Dec;51:136-42
pubmed: 26256469
J Subst Abuse Treat. 2021 May;124:108273
pubmed: 33771277
J Addict Med. 2020 Jul/Aug;14(4):e8-e9
pubmed: 32404652
Matern Child Health J. 2020 Sep;24(9):1104-1110
pubmed: 32564248
Subst Abus. 2019;40(2):170-177
pubmed: 30759047
Am J Drug Alcohol Abuse. 2016 Mar;42(2):203-12
pubmed: 26905228
J Addict Med. 2022 Jan-Feb 01;16(1):e44-e47
pubmed: 33606424
N Engl J Med. 2016 Dec 22;375(25):2504-2505
pubmed: 28002704
Contemp Clin Trials. 2020 Jun;93:106014
pubmed: 32353544
J Subst Abuse Treat. 2021 Feb;121:108197
pubmed: 33357606
J Subst Abuse Treat. 2021 Mar;122:108200
pubmed: 33250270
Am J Obstet Gynecol. 2020 Nov;223(5):770-772
pubmed: 32771380
Neuropsychopharmacology. 2009 Apr;34(5):1198-208
pubmed: 18563062
Reprod Health. 2021 Jan 18;18(1):10
pubmed: 33461593
J Reprod Infant Psychol. 2022 Nov;40(5):465-478
pubmed: 33870821
Obstet Gynecol. 2020 May;135(5):1038-1046
pubmed: 32282598
Nature. 2020 Aug;584(7820):175-176
pubmed: 32770149
Harm Reduct J. 2020 May 6;17(1):26
pubmed: 32375887
J Affect Disord. 2021 Mar 1;282:122-125
pubmed: 33412491
J Addict Med. 2020 Sep/Oct;14(5):e139-e141
pubmed: 32826619